Biotech
Novartis Faces A Tough Race For New Blockbuster Drugs
Novartis needs new blockbuster medicines to replace old hits as clinical trials hit fresh roadblocks.
Drug giant Novartis needs fresh hits. Old top-selling medicines are losing their patent protection. When patents end, cheap generic drugs take over sales.
The Swiss company wants new blockbuster drugs to fill the gap. Recent lab tests brought disappointing results for an experimental medicine. These setbacks slow down the race to replace lost income.
Big drug makers run on innovation. Failed clinical trials cost money and delay progress. Novartis still has other projects in testing, but the clock ticks fast.
Watch how big drug makers handle their test pipelines. Strong science creates steady profits for companies that plan ahead.
Source: CNBC
#Biotech#Novartis#Pharmaceuticals#Healthcare Stocks
More from Biotech
